Mayo Clinic Laboratories and Lucence announced a strategic collaboration on 10 January 2025 to increase global access to liquid biopsy testing. The partnership integrates molecular diagnostic tools into the Mayo Clinic Laboratories testing catalogue to assist with complex oncology cases.

• Technical Specifications: The collaboration utilises the LiquidHALLMARK assay, a next-generation sequencing tool that identifies clinically relevant biomarkers by analysing circulating tumour DNA (ctDNA) and RNA (ctRNA).
• Clinical Application: The test provides genomic profiling to identify targeted therapy options and includes graphical mapping to track molecular changes in tumours over time.
• Operational Scope: Testing will be facilitated through Lucence’s accredited laboratories in California and Singapore.

This summary is based on a press release issued by Lucence.